Saturday 17 October 2026
Export ANRO’s income statement to Excel — free account
Alto Neuroscience, Inc.
ANRO Healthcare Biotechnology
In the quarter to June 2026, EPS was flat, free cash flow fell 43.4% and total debt fell 15.7%, each against the same quarter a year earlier.
22.07
0.55
−2.43%
Follow ANRO
Alto Neuroscience, Inc. (ANRO) P/E ratio
Alto Neuroscience, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KURA Kura Oncology, Inc. compare | n/m |
| GLUE Monte Rosa Therapeutics, Inc. compare | n/m |
| ALMS Alumis Inc. compare | n/m |
| ANRO Alto Neuroscience, Inc. | n/m |
| MLTX MoonLake Immunotherapeutics compare | n/m |
| AKTS Aktis Oncology, Inc. compare | n/m |
| CGEM Cullinan Therapeutics, Inc. compare | n/m |
| JBIO Jade Biosciences, Inc. compare | n/m |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)